日本≥60岁成人接种JN.1适配新冠疫苗对症状性感染有效性的中期分析
日本2024-2025季节引入JN.1适配传统mRNA和自扩增mRNA(sa-mRNA)新冠疫苗,采用检测阴性设计评估≥60岁成人接种后对症状性SARS-CoV-2感染的有效性。共纳入954例符合条件发作,273例(28.6%)SARS-CoV-2阳性;联合疫苗≥7天VE为46.7%(95%CI:5.5-69.9),7-90天VE为51.6%(95%CI:5.0-75.4),>90天VE为35.9%(95%CI:-50.0-72.6);仅sa-mRNA疫苗≥7天VE为74.5%(95%CI:31.3-90.6)。JN.1适配mRNA疫苗接种对日本老年人症状性SARS-CoV-2感染提供保护。
要点
- JN.1适配传统与sa-mRNA疫苗联合接种≥7天对症状性感染VE为46.7%。
- 联合疫苗7-90天VE为51.6%,>90天VE为35.9%但置信区间宽。
- 仅sa-mRNA疫苗≥7天VE为74.5%,提示自扩增疫苗可能高保护。
核心结论
- JN.1适配mRNA疫苗接种(包括sa-mRNA疫苗)对日本≥60岁成人症状性SARS-CoV-2感染提供保护。
研究设计与样本
- eligible episodes定义为≥1个COVID-19样症状且进行SARS-CoV-2检测,共纳入954例发作。
- 使用混合效应逻辑回归估计疫苗有效性(VE)。
主要发现
- 954例发作中273例(28.6%)为SARS-CoV-2阳性。
- JN.1适配传统与sa-mRNA疫苗联合接种≥7天VE为46.7%(95%CI:5.5-69.9)。
- 联合接种7-90天VE为51.6%(95%CI:5.0-75.4),>90天VE为35.9%(95%CI:-50.0-72.6)。
- 仅JN.1适配sa-mRNA疫苗≥7天VE为74.5%(95%CI:31.3-90.6)。
临床怎么用
- 在≥60岁成人中,接种JN.1适配mRNA疫苗(含sa-mRNA)可降低症状性SARS-CoV-2感染风险。
- 接种后7-90天保护效果较高,>90天保护效果下降但置信区间宽,需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In Japan, JN.1-adapted conventional mRNA and self-amplifying mRNA (sa-mRNA) COVID-19 vaccines were introduced during the 2024-2025 season. We estimated the effectiveness of these vaccines against symptomatic SARS-CoV-2 infection among adults aged ≥60 years using a test-negative design (October 1, 2024-April 30, 2025). Eligible episodes were ≥1 COVID-19-like symptom and SARS-CoV-2 testing. Vaccine effectiveness (VE) was estimated using mixed-effects logistic regression. We included 954 episodes; 273 (28.6%) were SARS-CoV-2-positive. VE of combined JN.1-adapted conventional and self-amplifying mRNA vaccines was 46.7% (95% CI: 5.5-69.9) at ≥7 days, 51.6% (95% CI: 5.0-75.4) at 7-90 days, and 35.9% (95% CI: -50.0-72.6) at >90 days after vaccination. VE of the JN.1-adapted sa-mRNA vaccine alone was 74.5% (95% CI: 31.3-90.6) at ≥7 days. JN.1-adapted mRNA vaccination, including the sa-mRNA vaccine, was estimated to provide protection against symptomatic SARS-CoV-2 infection among older adults in Japan.
引用
- Maeda H, Igarashi A, Mitsui S, et al. Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025. Vaccine. 2026. PMID: 42501715. doi:10.1016/j.vaccine.2026.128964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。